Program
Anti-CD33 Antibody-drug Conjugate BL-M11D1
In Sichuan Biokin Pharmaceutical’s pipeline, CD33 ADC
. Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 43 open or running | phase 3since Nov 20, 2025 | Jun 16, 2023 | Dec 2026phase 1 · NCT05924750 |
- Named in Sichuan Biokin Pharmaceutical’s own pipeline as
BL-M11D1 (CD33 ADC)
, phase 1, as of Nov 16, 2026 (source).
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2023First study: phase 1 study in RecurrenceFirst studyNCT05924750 · 130 planned · China
- Nov 27, 2024Phase 1 study in Leukemia, Myeloid, AcuteNCT06714591 · 52 enrolled · United States
- Nov 20, 2025Phase 3 study in Leukemia, Myeloid, AcutePhase 3 reachedNCT07255872 · 216 planned · China
- May 9, 2026Phase 2 study in Myelodysplastic SyndromesNCT07591168 · 92 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in RecurrenceNCT05924750
- Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07255872
- Dec 2028Primary completion: phase 2 study in Myelodysplastic SyndromesNCT07591168
TargetBeta
“CD33 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of gemtuzumab, an immunoglobulin G4 (IgG4) monoclonal antibody directed against the CD33 antigen, ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07591168Myelodysplastic Syndromes · China | 2 | Not yet recruiting | Dec 2028 | 92 |
| NCT07255872Leukemia, Myeloid, Acute · China | 3 | Recruiting | Dec 2027 | 216 |
| NCT06714591Leukemia, Myeloid, Acute · United States | 1 | Terminated | Sep 16, 2026 | 52 |
| NCT05924750Recurrence · China | 1 | Recruiting | Dec 2026 | 130 |
How it is read
Names in the registry
- “BL-M11D1”, 4 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Myelodysplastic Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.